Plexium is a technology-first drug development company. We aim to improve efficiencies across the entire drug-development spectrum by leveraging techniques from various physical-science and computational disciplines.
In the near term we aim to enlarge the class of biological targets amenable to small-molecule modulation by recruiting the cells protein degradation machinery to targets of interest. Rather than use bi-functional molecules that link target-binders to E3 ligases, we develop ‘molecular glues’ that modify E3 ligase substrate-recognition. Our engineering background allows us to empirically search for molecular-glue degraders in massively high throughput cell-based assays utilizing DNA-encoded libraries.